Consumers’ motivation in responding to prescription drug advertising Consumers’ motivation in responding to prescription drug advertising by Nithima Sumpradit,

Slides:



Advertisements
Similar presentations
An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
Advertisements

OECD/INFE High-level Principles for the evaluation of financial education programmes Adele Atkinson, PhD OECD With the support of the Russian/World Bank/OECD.
@ PMCQ October 14, Agenda l PAAB info l Common Review Issues l Current Initiatives l Trends.
Competing interests Jaideep A Gogtay MD Conflict of Interest Employee of Cipla Ltd.
Socially Responsive Marketing
1 Health Surveys January 2008 Diane Martin, MA, PhD.
“Give me happiness vs. Take away our pain:” Consumers’ motivation in responding to prescription drug advertising Nithima Sumpradit, PhD 1 Frank J. Ascione,
International Seminar on Drug Advertising Canadian Experience Brazilian Health Surveillance Agency and Pan American Health Organization Brasilia, Brazil.
Advertising of rx medicinal products to the general public The case MSD Sharpe & Dohme GmbH vs. Merckle GmbH (C-316/09) Judgment of the ECJ of 5 May 2011.
The sources and quality of information for patients Andrew Herxheimer International Society of Drug Bulletins (ISDB) & Database of Individual Patients’
Culture Beth Lee November, 18, Culture and the Self (Markus & Kitayama, 1991) In Western cultures, the self is viewed as an independent, autonomous,
Separating Fact from Fiction
Governing Pharmaceutical Technologies in the Age of the Internet Nick Fox, Katie Ward and Alan O’Rourke University of Sheffield, UK.
The Nature of Groups Ch. 8.
Title slide PIPELINE QRA SEMINAR. PIPELINE RISK ASSESSMENT INTRODUCTION TO GENERAL RISK MANAGEMENT 2.
The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs Adam Atherly and Paul H. Rubin Emory University.
Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.
Clinical Pharmacy Basma Y. Kentab MSc..
Chapter One Copyright © 2006 McGraw-Hill/Irwin Marketing Research For Managerial Decision Making.
© 2005 by Nelson, a division of Thomson Canada Limited. 1 Business, Government, and Regulations Search the Web To keep abreast of changes in industrial.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Dr. Pornsri Laurujisawat 9April 09 1Dr.Pornsri Laurujisawat8/25/2015.
Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.
1 Advertising of Drugs ways Any drug advertising is forbidden Advertising to general public: non- prescription medicines, prescription-only drugs.
Objective The aim of this study was to investigate to which extent Direct-to-Consumer Advertising (DTCA) for pharmaceutical is disseminated-if present-
Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.
THE IMPACT OF NARRATIVE REPORTS ABOUT VACCINE ADVERSE EVENTS ON VACCINATION RISK PERCEPTION: A SIMULATION OF AN ONLINE PATIENT NETWORK Frank Renkewitz,
Online Medication Farrokh Alemi, PhD Based on Grahame-Smith, D. G. CBE lecture.
Consumer Information and Mobilization Processes Graca Cabral Grazyna Rokicka.
© University of Reading 2014www.reading.ac.uk Economic & Social Sciences Research Division 18 th Aug, 2015 Junjie Wu & Giuseppe Nocella Consumers psychological.
OECD/INFE Tools for evaluating financial education programmes Adele Atkinson, PhD Policy Analyst OECD With the support of the Russian/World Bank/OECD Trust.
Prescription Drug Disclosures Louis A. Morris, Ph.D. FTC-NAD Disclosure Workshop May 22, 2001.
“Delivering Therapeutic Agents” - Marketing and Communication Strategies of Drug Companies Safura Nantogmah.
Randomized Clinical Trials: The Versatility and Malleability of the “Gold Standard” Wing Institute Jack States Ronnie Detrich Randy Keyworth “Get your.
Ethics & International Management
 2008 Johns Hopkins Bloomberg School of Public Health Evaluating Mass Media Anti-Smoking Campaigns Marc Boulay, PhD Center for Communication Programs.
National Survey on Consumer Reaction to DTC Advertising of Prescription Medicines: Comments from DDMAC Kathryn J. Aikin, Ph.D. Division of Drug Marketing,
1 PhRMA Guiding Principles - DTC About Prescription Medicines.
1 Patient Communications Presented by: Carol Rothkopf December 7, 2005.
Good health, wellness, fitness, and healthy lifestyles are important for all people. Concept 1 Health, Wellness, Fitness & Healthy Lifestyles: An Introduction.
The Implications of Health Literacy for Customer-Centered Health Communication and Marketing Cynthia Baur, Ph.D. National Center for Health Marketing Centers.
Evaluating an Integrated Marketing Program. Chapter 15.
Keller and Heckman LLP Market Access and Trade Barriers and Practices: The Role of the Precautionary Principle and Other Non-Scientific Factors in Regulating.
Regulatory & Public Health Implications of DTCA Economists Conference Louis A. Morris, Ph.D. April 29, 2003.
Market research for a start-up. LEARNING OUTCOMES By the end of this lesson I will be able to: –Define and explain market research –Distinguish between.
Assessment of the Selection Process for the 2004 National List for Essential Drugs (NLED) of Thailand Yoongthong W 1, Kunaratanapruk S 1, Sumpradit N 1,
FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,
Overview of education in health care Chapter 1 1.
1 DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENTATIONS.
Interpersonal Psychotherapy Introduction and Overview.
FDA GUIDELINES FOR ADVERTISING COPYWRITERS At the end of this module, you will be able to recall FDA regulations related to pharmaceutical advertising.
Evaluation and Comparisons of Direct-to-Consumer Advertising of Prescription Drugs from the Internet April 11, 2003 Donald L. Sullivan R.Ph., Ph.D. Ohio.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Overview of Education in Health Care
THE SOUND OF SILENCE: AN EVALUATION OF CDC’S PODCAST INITIATIVE Quynh-Chau, M., Myers, Bradford A. (2013). The Sound of Silence: an evaluation of CDC's.
1 Meredith Rosenthal, Ph.D. May 10, 2007 Direct-to-Consumer Advertising of Prescription Drugs.
Motivation, Ability, and Opportunity
Marketing Drugs to Healthy Women with Certain Risk Factors: What might the FDA do to prevent doing more harm than good? APHA November 2007 Judy Norsigian.
APHA Convention - Washington, DC - Nov. 7, 2007
Motivation, Ability, and Opportunity
MKT 498 Education for Service-- snaptutorial.com.
MKT 498 Teaching Effectively-- snaptutorial.com
Culture Beth Lee November, 18, 2003.
Planning a Learning Unit
Performance Management
Thank you to the Congressional Public Health Caucus, which has brought us today to talk about an important issue that affects patient care and treatment,
Persuasion in Communication
Assessment of the Selection Process for the 2004 National List for Essential Drugs (NLED) of Thailand Yoongthong W1, Kunaratanapruk S1, Sumpradit N1,
Presentation transcript:

Consumers’ motivation in responding to prescription drug advertising Consumers’ motivation in responding to prescription drug advertising by Nithima Sumpradit, PhD 1 Frank J. Ascione, PharmD PhD 2 Richard P. Bagozzi, PhD 3 1 Thai Food and Drug Administration 2 University of Michigan 3 Rice University

Overview of direct-to-consumer advertising of prescription drugs (DTCA) –Evolution and Trends of DTCA –Effects of DTCA on consumers Research about DTCA –Research 1: Content analysis of DTCA –Research 2: Impact of DTCA on consumers Conclusions Talk outline Motivation & DTCA -Slide

Evolution & Trends of DTCA Motivation & DTCA -Slide Philosophy in public policy regarding consumer protection - Self-care movement - Competition in drug market - Emergence: - Introduced in the USA, USFDA requested the 2-year moratorium, USFDA issued the fair balance regulation for DTCA, Trends: - Adopted in New Zealand - Debated in Canada and EU - Placed concerns in developing countries

Types & Regulations of DTCA Motivation & DTC advertising -Slide Types of DTCAMajor componentsRegulation Product-specificBrand name + Indication“Fair-balance” regulation Print ad - Risk information - Brief summary (e.g., summary of a leaflet) TV or broadcast ad - Major (risk) statement - More information available at: - Health professionals - Toll-free number - Internet website - Print ad Help-seekingIndication onlyNo specific regulation (Physicians or health professionals as gatekeepers for Rx drugs) ReminderBrand name only

Effects of DTCA Motivation & DTC advertising -Slide Positive effectsNegative effects Create informed consumersCreate consumers’ demand Educate consumers about disease and treatment Improve MD-Pt relationship Lead to shared-decisions in healthcare Improve consumer health Misinform or mislead consumers about disease and treatment Create tension on MD-Pt relationship Lead to inappropriate decisions in healthcare Jeopardize consumer health

Research Motivation & DTC advertising -Slide Research 1: Content analysis of DTCA characteristics –Sumpradit N, Ascione FJ, Bagozzi RP. A cross-media content analysis of motivational themes in direct-to-consumer prescription drug advertising. Clinical Therapeutics. 2004; 26(1): Research 2: Impact of DTCA on consumer behavior –Sumpradit N, Ascione FJ, Bagozzi RP. “Give me happiness versus take away our pain”: Consumers’ motivation in responding to prescription drug advertising. (working manuscript)

Research 1: Content Analysis of DTCA Motivation & DTC advertising -Slide Goal: To examine motivational strategies used in DTCA Method: –Analyses of ads presented in 10 consumer magazines and 4 TV channel networks during Sep–Dec 2001 –Two drug classes Cox-2 inhibitors (Celebrex® vs. Vioxx®) Statin drugs (Lipitor®, Pravachol®, vs. Zocor®) –Three independent trained judges

Research 1(Results) Motivation & DTC advertising -Slide Cultural orientation –Use motivational themes that are consistent with cultural values. Ex. US ads rely on individualistic (as opposed to collectivistic) orientation. Goal orientation –Maximize the promise of obtaining positive outcomes –Minimized the chance that negative outcomes would occur Presentation style  Cognition –Maximize association between product and positive attributes Ex. Direct match of visual-verbal presentation in the benefit information announcement –Minimize association between product and negative attributes. Ex. No visual-verbal match in the risk information announcement

Research 2 Motivation & DTC advertising -Slide Cultural orientation –Use motivational themes that are consistent with cultural values. Ex. US ads rely on individualistic (as opposed to collectivistic) orientation. Goal orientation –Maximize the promise of obtaining positive outcomes –Minimized the chance that negative outcomes would occur Presentation style  Cognition –Maximize association between product and positive attributes Ex. Direct match of visual-verbal presentation in the benefit information announcement –Minimize association between product and negative attributes. Ex. No visual-verbal match in the risk information announcement Objective 1: How can the motivational themes persuade consumers to take actions? Objective 2: How can the motivational themes affect consumers’ ability to recall of risk information?

Goal compatibility Motivation & DTC advertising -Slide Motivation & DTC advertising -Slide TheoriesGoal Compatibility Self- regulatory focus theory Promotion focus Goal is to achieve positive outcomes Sensitive to presence/absence of positive outcome Focus on accomplishment Prevention focus Goal is to avoid negative outcomes Sensitive to presence/absence of negative outcome Focus on safety & obligation Self-construal orientation Independent self Goal is to achieve personal benefits (personal goals) Focus on uniqueness, self- reliance, self-fulfillment Interdependent self Goal is to achieve group benefits (collective goals) Focus on relationship, comply to duties, avoid conflicts Goal compatibility occurs when the ad combines:  Promotion focus with Independent self  Prevention focus with Interdependent self

Research 2 (Methodology) Motivation & DTC advertising -Slide Methods: –Design: Experiment based on a 2 (promotion vs. prevention) x 2 (independence vs. interdependence) factorial design –Sample: 220 females aged 40 years old or older –Data collection procedures: They were randomly assigned to view one of the four mock ads for cholesterol-lowering drug (Travacor) and completed a questionnaire. –Data analyses: Two-way ANOVA/ANCOVA

Intention to talk about high cholesterol with doctor (1 = definitely not to talk to 5 = definitely yes to talk with MD) Positive/Neutral DTCA attitudeNegative DTCA attitude Motivation & DTC advertising -Slide A D C B A D C B Research 2 (Persuasive effects of DTCA)

Research 2 (Effects on risk info recall) Exploratory AnalysisMain A. Positive/neutral DTCA attitude N=95 Neg. DTCA attitude N=102 Total N = 220 Promotion ads elicits risk information recall better than prevention ads 4.2 vs. 3.1, p = vs. 3.9, p = vs. 3.5, p = Motivation & DTC advertising -Slide Motivation & DTC advertising -Slide Motivation & DTC advertising -Slide

Conclusions Motivation & DTC advertising -Slide Failure of the drug distribution system (i.e., Rx drugs are accessible just like OTC drugs) remains unresolved. In Thailand, we prohibit prescription drugs to be advertised directly to consumers. So, why worry? DTCA is already here whether we are ready or not! Technology makes the world smaller.

Definitely shrunk if it’s a counterfeit drug. For questions about impotence diseases, please call [Insert Logos] Pfizer – an expert in research and development for pharmaceuticals for sexual impotence diseases Source: Home & Lady, August 2546